Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension Study to Study PQ-110-001 (NCT03140969) (INSIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03913130
Recruitment Status : Recruiting
First Posted : April 12, 2019
Last Update Posted : August 2, 2019
Sponsor:
Information provided by (Responsible Party):
ProQR Therapeutics

Brief Summary:
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.

Condition or disease Intervention/treatment Phase
Leber Congenital Amaurosis 10 Blindness Leber Congenital Amaurosis Vision Disorders Sensation Disorders Neurologic Manifestations Eye Diseases Eye Diseases, Hereditary Eye Disorders Congenital Retinal Disease Drug: QR-110 Phase 1 Phase 2

Detailed Description:

Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject.

Subjects will be given the opportunity to enroll into this extension study for continued dosing if available data support current and/or future benefits for the subject. The Investigator, in consultation and agreement with the Medical Monitor, will decide on enrollment of each individual subject, as well as on dosing of the first treated eye and treatment initiation of the contralateral eye. Continued subject treatment in this study is desirable, but cannot be guaranteed, since it will depend on the risks and benefit of further treatment on a case-by-case basis, as discussed and agreed upon with the Medical Monitor.

The contralateral eye and the first treated eye will be injected 3 months apart. The injection interval of 3 months between both eyes will limit burden for the subjects, with a 3 month-visit frequency during the course of the study. This between-eye interval could be adapted if safety data are supportive, and for logistic reasons, and in agreement with the Medical Monitor.

The same safety monitoring protocol and efficacy assessments will apply to both eyes.

QR-110 will be administered via intravitreal (IVT) injection.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Actual Study Start Date : May 13, 2019
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021


Arm Intervention/treatment
Experimental: Drug QR-110
First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
Drug: QR-110
First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration




Primary Outcome Measures :
  1. Frequency of ocular AEs [ Time Frame: 24 months ]
    Frequency of ocular adverse events (AEs)

  2. Frequency of non-ocular AEs [ Time Frame: 24 months ]
    Frequency of non-ocular AEs


Secondary Outcome Measures :
  1. Change in BCVA [ Time Frame: 24 months ]
    Change in Best Corrected Visual Acuity (BCVA)

  2. Change in Mobility course score [ Time Frame: 24 months ]
    Change in Mobility course score

  3. Change in photoreceptor outer segment layer thickness [ Time Frame: 24 months ]
    Change in photoreceptor outer segment layer thickness by Optical Coherence Tomography (OCT)

  4. Change in OCI [ Time Frame: 24 months ]
    Change in Oculomotor Instability (OCI)

  5. Change in FST blue [ Time Frame: 24 months ]
    Change in Full-Field Stimulus Testing (FST) - blue stimuli

  6. Change in FST red [ Time Frame: 24 months ]
    Change in Full-Field Stimulus Testing (FST) - red stimuli

  7. Change in VFQ-25 [ Time Frame: 24 months ]
    Change in Visual Function Questionnaire-25 (VFQ-25) score (adult subjects)

  8. Change in CVAQ [ Time Frame: 24 months ]
    Change in Cardiff Visual Ability Questionnaire for Children (CVAQC) score (pediatric subjects)

  9. Change in PLR [ Time Frame: 24 months ]
    Change in Pupillary Light Reflex (PLR) (latency and amplitude)

  10. Change in NIRAF [ Time Frame: 24 months ]
    Change in Near Infrared AutoFluorescence (NIRAF)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who completed participation in the study PQ-110-001 and who may derive benefit from continued treatment with QR 110, as assessed by the Investigator, in consultation with the Medical Monitor
  • Persistence of detectable outer nuclear layer (ONL) in the area of the macula in the opinion of the Investigator, as determined by OCT.
  • Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging, as assessed by the Investigator.
  • An adult (≥ 18 years) willing and able to provide informed consent for participation OR a minor (6 to < 18 years) with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures, and pediatric subjects able to provide age-appropriate assent for study participation.
  • Female subjects who have reached menarche and male subjects must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, highly effective methods of contraception for up to 3 months following their last dose QR-110. Acceptable methods of contraception are defined in the protocol. Women of non-childbearing potential may be included without the use of adequate birth control, provided they meet the criteria in the protocol.

Exclusion Criteria:

  • Any contraindication to IVT injection according to the Investigator's clinical judgment and international guidelines (Avery 2014).
  • Safety issue during study PQ-110-001 that may compromise subject safety when continued dosing, as determined by the Investigator, and in consultation with the Medical Monitor.
  • Any ocular or systemic disease or condition (including medications and laboratory test abnormalities) that could compromise subject safety or interfere with assessment of efficacy and safety, as determined by the Investigator and in consultation with the Medical Monitor.
  • Pregnant or breast-feeding female.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03913130


Contacts
Layout table for location contacts
Contact: Clinical Trials Manager +31 (0)88 1667000 clinical@proqr.com

Locations
Layout table for location information
United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
Principal Investigator: Steve Russel, MD         
United States, Pennsylvania
Scheie Eye Institute, University of Pennsylvania Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: Artur V Cideciyan, PhD         
Sub-Investigator: Samuele G Jacobson, MD         
Belgium
Ghent University Hospital and Ghent University Not yet recruiting
Ghent, Belgium, B-9000
Principal Investigator: Bart Leroy, MD         
Sponsors and Collaborators
ProQR Therapeutics
Investigators
Layout table for investigator information
Study Director: Lisa Grillone ProQR Medical Monitor

Additional Information:
Layout table for additonal information
Responsible Party: ProQR Therapeutics
ClinicalTrials.gov Identifier: NCT03913130     History of Changes
Other Study ID Numbers: PQ-110-002
First Posted: April 12, 2019    Key Record Dates
Last Update Posted: August 2, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ProQR Therapeutics:
LCA10
CEP290
p.Cys998X
c.2991+1655A>G
Leber's Congenital Amaurosis
Antisense oligonucleotide
RNA therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Blindness
Neurologic Manifestations
Vision Disorders
Sensation Disorders
Retinal Diseases
Leber Congenital Amaurosis
Eye Diseases, Hereditary
Eye Abnormalities
Genetic Diseases, Inborn
Disease
Eye Diseases
Pathologic Processes
Nervous System Diseases
Signs and Symptoms
Congenital Abnormalities